#ulonivirine
LightNews LightNews
iasociety.bsky.social
"Ulonivirine, an experimental non-nucleoside reverse transcriptase inhibitor, has the potential to be a component of once-weekly oral #HIV treatment, according to Phase II study results presented at #IAS2025 in #Rwanda."

@lizhighleyman.bsky.social @pozmagazine.bsky.social
Ulonivirine Shows Promise for Weekly Oral HIV Treatment
Study was halted early but the novel NNRTI is now being tested with a lower dose of islatravir.
www.poz.com
July 31, 2025 at 8:28 AM
shipragoelmd.bsky.social
#Skytorial #IDsky #HIVsky #IDMedEd @idsainfo.bsky.social

New HIV meds in pipeline/investigational
-MK8507 (Ulonivirine): NNRTI long half life 7-10 days, resistant profile similar to doravirine
-paired with nucleoside RT translocation inhibitor (islatravir)
November 27, 2024 at 2:47 AM
drlaurajwaters.bsky.social
Know your ULA (ultra long-acting) from your ULO (ulonivirine or MK-8507). Things evolve fast in HIV Medicine but our insistence on making things as confusing as possible with names/abbreviations stays stubbornly constant.....
*hivglasgow
November 11, 2024 at 2:09 PM
celtglobalhealth.bsky.social
Recently LAPaL updates

New drug delivery technologies:
Multi-Arm Polymer Conjugated Immunotherapies
Plexis Long-acting Injectable Technology

New drugs:
GS-3242
Acoziborole

And we've updated:
Ulonivirine
VH-499
VH-148
Alimatravir
GS-3107
www.liverpool.ac.uk/celt-global-...
@medicinespatentpool.org
The LAPaL logo is the word LAPaL with 'the long-acting therapeutics patents and licences database' underneath.
March 31, 2026 at 11:01 AM
aidsmap.bsky.social
Islatravir plus ulonivirine shows promise for weekly oral HIV treatment
@iasociety.bsky.social @aidsconference.bsky.social #AIDS2026
www.aidsmap.com/news/jul-202...
www.aidsmap.com
July 31, 2026 at 1:16 PM
hiv-i-base.bsky.social
24-week phase 2 results of once-weekly oral ART with #ulonivirine + #islatravir, plus other studies on this combination at #IAS2025:

i-base.info/htb/51965

Good efficacy and safety – with a larger phase 2b study already ongoing using 200mg ULO and 2 mg ISL doses.

#HIVsky #HIVtreatment #HIVresearch
i-Base graphic for IAS 2025. The main text reads: Once-weekly oral ART. New research that might make HIV meds even easier to take. At the top is i-Base’s website address: I hyphen base dot info. In the bottom left it says: HIV treatment bulletin. In the bottom right is a white box, containing the words: IAS 2025. 13th to 17th July. Above this is a spiral next to the red AIDS ribbon. There are horizontal strips of the IAS 2025 signature graphics at the top and bottom of the image. They are made up of squares, each containing its own unique pattern based on traditional Rwandan art. The colours used in the image are red, black, white and grey.
August 15, 2025 at 1:46 PM
ameshaa.bsky.social
“several favorable characteristics of ulonivirine, including its ability to retain activity against most variants resistant to other first- and second-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) in its class” www.medpagetoday.com/meetingcover...
Investigational Once-Weekly ART Combo Maintained Viral Suppression in HIV
However, the trial was stopped early due to decreases in total lymphocyte and CD4 counts
www.medpagetoday.com
July 17, 2025 at 12:09 PM
scooper-id.bsky.social
Among participants with available data, all remained virologically suppressed with islatravir 20 mg and ulonivirine at dosages of 100 mg, 200 mg, or 400 mg. The findings were presented at the International AIDS Society Conference on HIV Science.
July 17, 2025 at 12:45 PM